Serum Cyfra 21-1 as a co-variable in future NSCLC chemotherapy trials.
Watine
J
J
D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D011379:Prognosis; D015203:Reproducibility of Results; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D053539:Keratin-19; C102012:antigen CYFRA21.1; D007633:Keratins